Novocure Ltd (NVCR)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 11:06 AM ET
Novocure Ltd (NVCR) Earnings: Report Dates and Results
In the quarter ended Sep 30, 2026, Novocure reported EPS of -$0.09, above the -$0.21 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NVCR's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.
NVCR Earnings Call
The latest NVCR earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 39 quarters below that had an estimate, NVCR beat 23 and missed 16. Revenue for the quarter ended Sep 30, 2026 was $193.40M, up 15.7% from $167.20M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.09 | -$0.21 | -$0.31 - -$0.14 | +57.14% | Beat | N/A | 7 | 1 up, 0 down | Oct 29, 2026 | $193.40M |
| Jun 30, 2026 | -$0.13 | -$0.30 | -$0.40 - -$0.23 | +56.67% | Beat | N/A | 6 | 5 up, 2 down | Jul 23, 2026 | $183.58M |
| Mar 31, 2026 | -$0.62 | -$0.51 | -$0.83 - -$0.34 | -21.57% | Miss | N/A | 7 | 0 up, 2 down | Apr 30, 2026 | $174.06M |
| Dec 31, 2025 | -$0.22 | -$0.41 | -$0.47 - -$0.30 | +46.34% | Beat | N/A | 7 | 2 up, 4 down | Feb 26, 2026 | $174.35M |
| Sep 30, 2025 | -$0.33 | -$0.42 | -$0.48 - -$0.37 | +21.43% | Beat | N/A | 8 | 3 up, 3 down | Oct 30, 2025 | $167.20M |
| Jun 30, 2025 | -$0.36 | -$0.39 | -$0.46 - -$0.36 | +7.69% | Beat | N/A | 7 | 6 up, 0 down | Jul 24, 2025 | $158.81M |
| Mar 31, 2025 | -$0.31 | -$0.46 | -$0.74 - -$0.26 | +32.61% | Beat | N/A | 7 | 0 up, 0 down | Apr 24, 2025 | $154.99M |
| Dec 31, 2024 | -$0.61 | -$0.36 | -$0.44 - -$0.27 | -69.44% | Miss | N/A | 7 | 3 up, 0 down | Feb 27, 2025 | $161.27M |
| Sep 30, 2024 | -$0.28 | -$0.33 | -$0.41 - -$0.23 | +15.15% | Beat | N/A | 7 | 0 up, 1 down | Oct 30, 2024 | $155.09M |
| Jun 30, 2024 | -$0.31 | -$0.40 | -$0.46 - -$0.30 | +22.50% | Beat | N/A | 6 | 0 up, 0 down | Jul 25, 2024 | $150.36M |
| Mar 31, 2024 | -$0.36 | -$0.42 | -$0.52 - -$0.36 | +14.29% | Beat | N/A | 7 | 0 up, 0 down | May 2, 2024 | $138.50M |
| Dec 31, 2023 | -$0.45 | -$0.52 | -$0.61 - -$0.47 | +13.46% | Beat | N/A | 7 | 0 up, 0 down | Feb 22, 2024 | $133.78M |
| Sep 30, 2023 | -$0.46 | -$0.52 | -$0.57 - -$0.43 | +11.54% | Beat | N/A | 6 | 0 up, 0 down | Oct 26, 2023 | $127.32M |
| Jun 30, 2023 | -$0.54 | -$0.50 | -$0.53 - -$0.46 | -8.00% | Miss | N/A | 5 | 0 up, 1 down | Jul 27, 2023 | $126.05M |
| Mar 31, 2023 | -$0.50 | -$0.34 | -$0.45 - -$0.22 | -47.06% | Miss | N/A | 8 | 0 up, 0 down | May 4, 2023 | $122.18M |
| Dec 31, 2022 | -$0.36 | -$0.30 | -$0.45 - -$0.24 | -20.00% | Miss | N/A | 8 | 0 up, 0 down | Feb 23, 2023 | $128.43M |
| Sep 30, 2022 | -$0.25 | -$0.26 | -$0.39 - -$0.13 | +3.85% | Beat | N/A | 7 | 0 up, 0 down | Oct 27, 2022 | $131.00M |
| Jun 30, 2022 | -$0.23 | -$0.14 | -$0.25 - -$0.06 | -64.29% | Miss | N/A | 9 | 0 up, 0 down | Jul 28, 2022 | $140.87M |
| Mar 31, 2022 | -$0.04 | -$0.18 | -$0.30 - -$0.10 | +77.78% | Beat | N/A | 8 | 0 up, 0 down | Apr 28, 2022 | $137.55M |
| Dec 31, 2021 | -$0.25 | -$0.10 | -$0.14 - -$0.07 | -150.00% | Miss | -725.0% | 8 | 0 up, 0 down | Feb 24, 2022 | $133.21M |
| Sep 30, 2021 | -$0.13 | -$0.06 | -$0.15 - $0.00 | -116.67% | Miss | -244.4% | 9 | 0 up, 1 down | Oct 28, 2021 | $133.61M |
| Jun 30, 2021 | -$0.14 | $0.01 | -$0.03 - $0.05 | N/A | N/A | -800.0% | 9 | N/A | Jul 29, 2021 | $133.52M |
| Mar 31, 2021 | -$0.04 | $0.01 | -$0.02 - $0.06 | -500.00% | Miss | -200.0% | 9 | N/A | Apr 29, 2021 | $134.69M |
| Dec 31, 2020 | $0.04 | $0.12 | $0.07 - $0.20 | -66.67% | Miss | 0.0% | 9 | N/A | Feb 25, 2021 | $143.95M |
| Sep 30, 2020 | $0.09 | $0.04 | $0.01 - $0.06 | +125.00% | Beat | +350.0% | 9 | N/A | Oct 29, 2020 | $132.66M |
| Jun 30, 2020 | $0.02 | $0.01 | -$0.03 - $0.04 | +100.00% | Beat | N/A | 8 | N/A | Jul 30, 2020 | $115.92M |
| Mar 31, 2020 | $0.04 | $0.02 | -$0.05 - $0.07 | +100.00% | Beat | N/A | 7 | N/A | Apr 30, 2020 | $101.83M |
| Dec 31, 2019 | $0.04 | $0.02 | -$0.05 - $0.05 | +100.00% | Beat | N/A | 7 | N/A | Feb 27, 2020 | $99.23M |
| Sep 30, 2019 | $0.02 | -$0.04 | -$0.10 - $0.02 | +150.00% | Beat | N/A | 6 | N/A | Oct 31, 2019 | $92.06M |
| Jun 30, 2019 | -$0.01 | -$0.06 | -$0.13 - -$0.01 | +83.33% | Beat | N/A | 7 | N/A | Jul 25, 2019 | $86.71M |
| Mar 31, 2019 | -$0.13 | -$0.15 | -$0.27 - -$0.04 | +13.33% | Beat | N/A | 6 | N/A | May 2, 2019 | $73.31M |
| Dec 31, 2018 | -$0.17 | -$0.13 | -$0.17 - -$0.09 | -30.77% | Miss | N/A | 5 | N/A | Feb 28, 2019 | $69.67M |
| Sep 30, 2018 | -$0.13 | -$0.14 | -$0.17 - -$0.12 | +7.14% | Beat | N/A | 5 | N/A | Oct 25, 2018 | $64.76M |
| Jun 30, 2018 | -$0.17 | -$0.16 | -$0.19 - -$0.11 | -6.25% | Miss | N/A | 5 | N/A | Jul 26, 2018 | $61.51M |
| Mar 31, 2018 | -$0.23 | -$0.13 | -$0.15 - -$0.11 | -76.92% | Miss | N/A | 5 | N/A | Apr 26, 2018 | $52.13M |
| Dec 31, 2017 | -$0.12 | -$0.11 | -$0.18 - -$0.03 | -9.09% | Miss | N/A | 6 | N/A | Feb 22, 2018 | $53.66M |
| Sep 30, 2017 | -$0.13 | -$0.14 | -$0.23 - $0.02 | +7.14% | Beat | N/A | 6 | N/A | Oct 26, 2017 | $50.11M |
| Jun 30, 2017 | -$0.24 | -$0.22 | -$0.26 - -$0.16 | -9.09% | Miss | N/A | 5 | N/A | Jul 27, 2017 | $38.38M |
| Mar 31, 2017 | -$0.21 | -$0.20 | N/A | -5.00% | Miss | N/A | N/A | N/A | Apr 27, 2017 | $34.88M |
| Dec 31, 2016 | -$0.26 | -$0.39 | N/A | +33.33% | Beat | N/A | N/A | N/A | Feb 23, 2017 | $30.24M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.22, after -$1.56 the year before. It was -$1.47 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.22 | N/A |
| Dec 31, 2024 | -$1.56 | N/A |
| Dec 31, 2023 | -$1.95 | N/A |
| Dec 31, 2022 | -$0.88 | N/A |
| Dec 31, 2021 | -$0.56 | -394.7% |
| Dec 31, 2020 | $0.19 | N/A |
| Dec 31, 2019 | -$0.08 | N/A |
| Dec 31, 2018 | -$0.70 | N/A |
| Dec 31, 2017 | -$0.70 | N/A |
| Dec 31, 2016 | -$1.47 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,300 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,289 | 11 | |
| 2026Q2 | Jun 30, 2026 | 5,390 | 12 | |
| 2026Q1 | Mar 31, 2026 | 5,733 | 13 | |
| 2025Q4 | Dec 31, 2025 | 4,307 | 10 | |
| 2025Q3 | Sep 30, 2025 | 6,572 | 11 | |
| 2025Q2 | Jun 30, 2025 | 6,772 | 13 | |
| 2025Q1 | Mar 31, 2025 | 7,017 | 13 | |
| 2024Q4 | Dec 31, 2024 | 5,539 | 11 |
2026Q3 Earnings Call
Opening remarks
Adam Daney Investor Relations Good morning, and thank you for joining us to review Novocure's third quarter 2026 performance. I am joined on the phone today by our Executive Chairman, Bill Doyle; CEO, Frank Leonard; Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Results. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements. Actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, and specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to capital structure, tax rate, and material noncash items, and best reflects the financial value generated by our business. We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure, net income, without reasonable efforts. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides, and in our Form 10-Q filed with the SEC today. These materials can be accessed from the Investor Relations page of our website. Following our prepared remarks, we will open the line for questions. I will now turn the call over to our Executive Chairman, Bill Doyle.
William F. Doyle Executive Chairman Thank you, Adam. This morning, Novocure reported results for the third quarter of 2026. This quarter was marked by solid execution, with continued momentum in our Optune Gio business and our promising launch of Optune Lua in Japan. We reached a record number of active patients on therapy, generated record-high quarterly net revenue, and made strong progress on our path to profitability. We experienced headwinds in our Optune Pax launch this quarter, but remain committed to establishing TTFields therapy in the evolving PDAC standard of care. As we enter the final months of the year, we are on track to achieve our 2026 goals, and we believe we are well positioned to drive this positive momentum into 2027. I will begin this morning with a review of our Optune Gio and Optune Maya programs.
Frequently Asked Questions About NVCR
Did NVCR beat earnings estimates last quarter?
Yes. Novocure reported EPS of -$0.09 for the quarter ended Sep 30, 2026, above the -$0.21 estimate, a 57.14% surprise.
What EPS do analysts expect from NVCR next quarter?
The consensus EPS estimate for Novocure for the quarter ending Dec 31, 2026 is -$0.24 from 9 analysts, with estimates from -$0.30 to -$0.20.
How often does NVCR beat earnings estimates?
Novocure beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +16.36%.
NVCR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts